# Sacubitril/Valsartan Versus Valsartan for Hypertensive Patients With Acute Myocardial Infarction

Study · id `cardio:ct-nct05060588` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05060588](<https://clinicaltrials.gov/study/NCT05060588>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05060588

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: High blood pressure; Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT05060588. Randomized; triple masking; primary purpose treatment. Start 2021-10 (anticipated); primary completion 2022-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT05060588, source copy `cardio:ctgov-nct05060588-2021-09-29`, retrieved 2026-10-26)
- Planned start: 2021-10 (anticipated) (ClinicalTrials.gov record NCT05060588, source copy `cardio:ctgov-nct05060588-2021-09-29`, retrieved 2026-10-26)
- Primary completion: 2022-10 (anticipated) (ClinicalTrials.gov record NCT05060588, source copy `cardio:ctgov-nct05060588-2021-09-29`, retrieved 2026-10-26)
- Completion: 2023-02 (anticipated) (ClinicalTrials.gov record NCT05060588, source copy `cardio:ctgov-nct05060588-2021-09-29`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05060588, source copy `cardio:ctgov-nct05060588-2021-09-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05060588-2021-09-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Sacubitril/Valsartan Versus Valsartan for Hypertensive Patients With Acute Myocardial Infarction
- Condition: Myocardial Infarction
- Condition: Hypertension
- Intervention (Drug): Sacubitril/Valsartan 49/51mg/Tab
- Intervention (Drug): Valsartan 80mg/Tab
- Lead sponsor: Qingdao Central Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Qingdao Central Hospital (`cardio:org-qingdao-central-hospital`)

## Provenance

Content hash: e0591874990c20d7984c50f1ca33e9115eccc1b53c743efa2d56587c087f99c0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
